Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
Daiichi Sankyo saw its group sales in FY2018 slip 3.2% year on year to 929.7 billion yen as big growth from its anticoagulant hopeful Lixiana (edoxaban) failed to offset the impact of generic inroads into its flagship hypertension drug Olmetec…
To read the full story
Related Article
- Daiichi Sankyo Enjoys 7.7% Rise in April-December Sales; Enhertu Off to Solid Start
February 3, 2020
- Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
- Daiichi Sankyo Logs Double-Digit Growth in Q1 as Olmetec Cliff Tails Off; Profit Zooms on AZ Deal, Asset Sale
August 1, 2019
- Daiichi Sankyo to Move Up Japan Filing of DS-8201 to FY2019 H2
April 26, 2019
- Daiichi Sankyo Aims to File Yescarta in Japan by Year-End
April 26, 2019
- Daiichi Sells Nihonbashi Building to Raise Funds for Oncology R&D
April 26, 2019
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
May 1, 2018
BUSINESS
- Alexion Japan Wants to Extend 2-Digit Growth, Ride on Reform Boon: Next Chief
November 15, 2024
- EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
- Stella Pharma Ties Up with TLS for Borofalan in US, Europe
November 15, 2024
- MSD Files PAH Treatment Sotatercept in Japan
November 15, 2024
- Keytruda Maintains Top-Selling Title in Japan in July-September: IQVIA
November 14, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…